{'fraction_non_alphanumeric': 0.03753431708991078, 'fraction_numerical': 0.022391901166781056, 'mean_word_length': 4.924523506988564, 'pattern_counts': {'":': 0, '<': 6, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Long Non-coding RNA X-Inactive Specific Transcript Mediates Cell Proliferation and Intrusion by Modulating the miR-497/Bcl-w Axis in Extranodal Natural Killer/T-cell Lymphoma

The present study was directed toward laying new findings for Extranodal natural killer/T-cell lymphoma (ENKL)-oriented therapy with a focus on long non-coding RNA (lncRNA)–microRNAs (miRNAs)–mRNA interaction. The expression and function of XIST (X-inactive specific transcript) were analyzed both in vivo and in vitro. The online database of lncRNA-miRNA interaction was used to screen the target of XIST, and miR-497 was selected. Next, the predicted binding between XIST and miR-497, and the dynamic effect of XIST and miR-497 on downstream Bcl-w was evaluated. We found that XIST dramatically increased in the blood of ENKL patients and cell lines. XIST knockdown suppressed the cell proliferation and migration in vivo and in vitro. Herein, we confirmed the negative interaction between XIST and miR-497. Moreover, XIST knockdown reduced the protein levels of Bcl-w, a downstream target of miR-497. XIST sponges miR-497 to promote Bcl-w expression, and finally modulating ENKL cell proliferation and migration. To be interested, inhibition of Bcl-w by ABT737 can overcome the high expression of XIST, and suppressed the ENKL proliferation and migration by inducing apoptosis. This study provided a novel experimental basis for ENKL-oriented therapy with a focus on the lncRNA–miRNA–mRNA interaction.


INTRODUCTION
Non-Hodgkin's lymphoma (NHL) stems from B, T, and natural killer (NK) lymphocytes and comprises both indolent and aggressive types (Swerdlow et al., 2016). Extranodal NK/T-cell lymphoma (ENKL), nasal type, is an aggressive NHL representing a rare specific extranodal subtype of peripheral T-cell lymphoma (PTCL) (Tse and Kwong, 2017). ENKL occurs mainly (80%) in the nose, and upper aerodigestive tract, with only a small proportion (20%) observed in non-nasal areas (Au et al., 2009). ENKL is an aggressive lymphoma with poor survival in an untreated patient measured in weeks to months; the median overall survival is 3 years for localized disease and 8 months for metastatic disease (Lee et al., 2006). Currently, there is no single standard of care for the treatment of ENKL. Radiation and/or chemotherapy are generally used in all ENKL patients, but with very limited effects. Therefore, new molecular targeted therapies are required for the treatment of ENKL malignancies.
A recent study has indicated that most long non-coding RNAs (lncRNAs) possibly acts as molecular miRNAs sponges and release RNA transcripts that are targeted by active miRNAs (Wang and Chang, 2011). LncRNAs, comprising over 200 nucleotides, regulates gene expression through sponging miRNA and stabilizing mRNA (Batista and Chang, 2013). LncRNA expression is reduced in several cancers, confirming its oncogenic and anti-tumor effects, which, in turn, suggest that abnormal lncRNA expression is implicated in cancer progression to a considerable extent (Sanchez Calle et al., 2018). Nowadays, the lncRNA X-inactive-specific transcript (XIST) has garnered considerable attention, given that it is dramatically augmented in many types of cancer and might represent a promising oncogene (Sorensen et al., 2013). Moreover, XIST is transcribed from an X inactivation center that is directly connected with polycomb inhibitory complex 2, which controls histone H3 trimethylation at Lys27, inactivating the X chromosome (Ma et al., 2017). Regarding hematologic malignant tumors, lncRNAs have been well investigated in B-cell lymphoma/leukemia  but rarely researched in ENKL.
Here we investigated XIST expression level in ENKL patients and found that XIST was upregulated in these patients compared with healthy participants. We searched for downstream target miRNAs of XIST and found that miR-497/Bcl-w is a target of XIST. And miR-497 interacts with XIST, mediating ENKL cell proliferation and migration. Collectively, the present study laid a new experimental foundation for ENKL-oriented therapy with a focus on the lncRNA-miRNA-mRNA interaction. University and was conducted following relevant regulations and the Declaration of Helsinki. The study was approved to be conducted with obtaining informed consent from patients and donors. A small proportion of samples were collected to ensure the integrality of the remaining tissues. The relevant data were derived from the medical record library through a double-blind program and were analyzed anonymously so that the interest of patients would not be damaged.
Lipofectamine 2000 was applied to the transfection of miR-497 mimics, antagomir, Bcl-w siRNA, and negative control (NC) into cells. The miRNA mimics, antagomir, and NC were prepared by GenePharma as previously reported . The sequences for the siRNA of Bcl-w were GCAGACUUUGUAGGUUAUATT (siRNA 1) and GGC GGAGUUCACAGCUCUAUA (siRNA 2).

Cell Proliferation Assay
Extranodal natural killer/T-cell lymphoma cell proliferation was determined using the cell counting Kit-8 (CCK8) and 5-Bromo-2 -deoxyUridine (BrdU) assays. An improved CCK8 assay was applied to assess cell viability. Cells were inoculated in 96-well plates (5 × 10 3 cells/well) and transfected for 2 days before adding 0.1 mL CCK8; 4 h later, A 450 was determined through enzyme labeling.
The BrdU assay was applied to determine cell proliferation using the Cell Proliferation Detection kit as per manufacturer's instructions.

Transwell Migration Assay
A cell suspension (0.2 mL) in FBS free medium was transferred to the upper transwell chambers (8 µm). RPMI-1640 (0.6 mL) with 10% FBS was added to the lower chambers. After 24 h of culture, viable ENKL cell numbers were counted on a hemocytometer by the Erythrosin B (Sigma Chemical Co., St. Louis, MO, United States) dye exclusion assay. The relative migration was calculated by comparing the migrated cell number with the control group.

Dual-Luciferase Reporter Assay (DLRA)
After amplification through PCR, the XIST fragment was cloned into the Renilla psiCHECK2 vector downstream as previously described , which was termed wt-XIST. The primers used were 5 -CCGCTCGAGcatagttctgttagttacac-3 , and 5 -AATGCGGCCGCatgcaattatgcatatcaac-3 , including XhoI and NotI. The XIST seed region underwent mutation to eliminate all miR-497 nucleotides 2-7 complementarity, thereby obtaining the XIST mutant reporter, which was termed mut-XIST. The primers for site mutation were 5 -tgtcctc tttgccatACGACGAgagttctgactaccc-3 , and 5 -gggtagtcagaactc TCGTCGTatggcaaagaggaca -3 . The Bcl-w wild type and mutated luciferase reporters were constructed as previously described (Yin et al., 2010). HEK293 cells were cultured in 24-well plates overnight, followed by co-transfection with the indicated vectors and miR-497 mimics. Two days later, LRA was performed using the DLRA System. Renilla luciferase activity was standardized with Firefly luciferase as the reference.

RNA Immunoprecipitation (RIP)
RNA Immunoprecipitation was performed using the Magna RIP RNA-Binding Protein Immunoprecipitation Kit, and RNA for in vitro experiments was transcribed using the RNA Synthesis Kit as per manufacturer's instructions. miR-497, IgG, and XIST levels in immunoprecipitates were measured via qRT-PCR.

Animals
Balb/c athymic nude male mice (42 days old) were provided by Guangdong Medical Animal Center. All relevant operations were performed as per the NIH regulations regarding experimental animals' use and care and were approved by Institutional Animal Care and Use Committee. The 2 × 10 6 SNK-6 with or without XIST shRNA stable expression was washed, incubated in PBS, and subsequently injected into the lateral caudal vein or flank (0.1 mL). When the weight of the mice decreased to <20% of the original weight, they were executed. For flank xenografts, the tumor was harvested for Ki-67 staining. Six mice were used in each group of experiments. For caudal vein injection, the lungs of the executed mice were separated, followed by fixation with 10% formaldehyde solution. A dissecting microscope was used to observe the surface metastasis number in a single lung.

Data Analysis
Data were analyzed using SPSS17.0 and expressed as average ± SD obtained from not less than three parallel experiments. Student's t-test was used to analyze the statistical differences in means where applicable. Analysis of variance was used for estimating intergroup differences. * P < 0.05; * * P < 0.01.

XIST Expression in ENKL Patients
To study the role of XIST in ENKL, we first analyzed XIST mRNA levels in the blood sample collected from 54 ENKL patients and 24 healthy donors. The findings demonstrated that XIST expression was notably upregulated in ENKL patients ( Figure 1A). ENKL patients were classified into two groups based on their clinical stages (n = 41 for stage I, II; n = 13 for stages III, IV). XIST expression levels were significantly higher in stage III and IV ENKL patients ( Figure 1B). The 54 patients were further classified into high (higher than average, n = 29) and low (lower than average, n = 25) XIST expression groups. High XIST expression contributed to unfavorable clinical outcomes in these 54 ENKL patients ( Figure 1C). To thoroughly explore the exact role of XIST that is involved in ENKL and the relevant molecular mechanism, PCR was used to determine XIST expression in four ENKL cell lines and one normal human PBMC line. XIST expression was dramatically augmented in ENKL cells, which was consistent with its high expression in the tissue samples ( Figure 1D). Therefore, our data suggest that XIST is upregulated in ENKL patients and is correlated to poor patient survival.

XIST Promotes ENKL Cell Proliferation and Migration
To study the role of XIST on ENKL progression, XIST shRNA was transfected into SNK-6 and SNT-8 cells. The XIST expression was mirrored by real-time PCR (Figure 2A). Subsequently, the growth of the transfected cells was detected using BrdU and CCK8 assays. XIST knockdown notably inhibited cell proliferation (Figures 2B,C). The transwell assay revealed that the depletion of XIST suppressed cell migration ( Figure 2D). We further analyzed the expression of cell proliferation, invasion, and migration markers including Ki-67, MMP7, MMP9, E-cadherin, and vimentin. Our data showed that the absence of XIST suppressed Ki-67, MMP7, MMP9, and vimentin expression but enhanced E-cadherin expression ( Figure 2E and Supplementary Figure 1A). To further confirm the function  Figure 1C). Therefore, these findings revealed that XIST is associated with ENKL proliferation and migration in vitro.

Knocking Down XIST Inhibits ENKL Tumor Growth and Metastasis in vivo
To confirm that XIST plays a role in the growth of ENKL in vivo, the growth of SNK-6 xenografts in nude mice was examined. SNK-6 cells with or without stable XIST knockdown were inoculated subcutaneously into nude mice. The tumors with XIST knockdown had a slower growth rate and a smaller size than those with control shRNA transfection (Figures 3A,B). Furthermore, Ki-67 staining revealed that the depletion of XIST suppressed tumor proliferation (Figure 3C). A tumor metastasis model by tail-vein injection of tumor cells was used to investigate whether XIST promotes metastasis. SNK-6 cells with or without stable XIST knockdown were injected into nude mice via tail vein injection. Five weeks after the injection, the mice were sacrificed to observe tumor formation in the lungs. Metastatic tumors were present and verified through H&E staining of sectioned lung tissue excised from the mice. We found that the tumor size and number were smaller in the mice injected with stable XIST knockdown SNK-6 cells (Figures 3D,E). Without XIST in tumor cells, the mice exhibited better survival ( Figure 3F). Collectively, these results indicate that XIST expression mediates ENKL growth and metastasis in vivo.

XIST Promotes ENKL Proliferation and Migration by Targeting miR-497
LncRNAs generally function by interacting with downstream target miRNAs (Paraskevopoulou and Hatzigeorgiou, 2016). To explore whether XIST regulates the proliferation and migration of ENKL cells by interacting with miRNAs, we scanned the online databases Mircod 1 and lncBase v.2 2 for XIST interacting miRNAs. We selected the top five miRNAs in the overlap of these two databases, including miR-499, miR-141, miR-497, miR-182, and let-7b ( Figure 4A). Next, we analyzed the expression of these five miRNAs in SNK-6 cells with XIST knockdown or overexpression. We found only miR-497 expression in ENKL patients was downregulated compared with that in healthy donors (Figure 4B), showing that miR-497 is a likely target of XIST. We further analyzed miR-497 mRNA levels in ENKL cells with XIST overexpression or knockdown. Our results revealed that XIST overexpression suppressed miR-497 in NK-92 cells (Figure 4C), but XIST knockdown enhanced miR-497 expression in ENKL cells (Figure 4D). The miR-497 expression was also higher in the xenografted tumors with XIST knockdown (Figure 4E). To further verify miR-497 as a target of XIST, a specific biotin-marked miR-497 probe successfully captured XIST ( Figure 4F). Dual-luciferase reporter assay (DLRA) was also used to investigate the direct relevance of miR-497 and XIST according to their complementary sequences. Wild-type (WT) or mutant XIST fragments were established and introduced into the luciferase reporter gene downstream. Next, the miR-497 mimic with the reporter gene was co-transfected into SNK-6 cells. A noticeable decrease in WT luciferase reporter activity was detected in relation to control RNA co-transfection ( Figure 4G). However, miR-497 co-transfection did not affect mutant luciferase reporter activity ( Figure 4G). Furthermore, the expression of XIST in ENKL patients was negatively correlated with the expression of miR-497 (Supplementary Figure 2A). Obviously, a direct relationship between XIST and miR-497 was verified.
To further investigate whether miR-497 is necessary for ENKL proliferation and migration driven by XIST, we transfected the stable XIST knockdown SNK-6 cells with miR-497 antagomir. Consistent with our hypothesis, miR-497 inhibition counteracted the suppressive effect of XIST depletion on the proliferation and migration of ENKL cells (Figures 4H-J). Furthermore, transfection of the miR-497 mimic in SNK-6 and SNT-8 cells phenocopied the effect of XIST depletion, which also suppressed the proliferation and migration of ENKL cells ( Supplementary  Figures 2B-D). Collectively, these findings indicate that miR-497 is the downstream target of XIST in the proliferation and migration of ENKL cells.

Bcl-w Is a Direct Target of miR-497 in ENKL Cells
Previously, miR-497 has been identified as a tumor inhibitor based on its effects on Bcl-w, (Shen et al., 2012) an anti-apoptosis Bcl-2 protein that plays an essential part in cell survival. Here we investigated whether Bcl-w could be modulated by the XIST/miR-497 axis. We found that Bcl-w was downregulated in XIST shRNA-transfected ENKL cells (Figures 5A,B). Transfection of miR-497 mimic into ENKL cells also suppressed Bcl-w protein and mRNA levels (Figures 5C,D). Conversely, transfection of miR-497 antagomir abolished the suppressive effect of XIST depletion on Bcl-w expression (Figures 5E,F). The mRNA level of Bcl-w was also lower in the xenografted tumors with XIST knockdown (Figure 5G). Furthermore, we co-transfected the Bcl-w luciferase reporter vector with miR-497 or control miRNA into SNK-6 cells and determined the luciferase activity. The results showed that miR-497 considerably suppressed luciferase activity relative to NC miRNA ( Figure 5H). However, miR-497 did not suppress the luciferase activity of the reporter vector containing Bcl-w 3 -UTR with a three-point mutation in the miR-497-connecting site ( Figure 5H). Furthermore, the mRNA level of Bcl-w in primary ENKL tumors was also higher than that in healthy tissues ( Figure 5I) and was positively correlated with the XIST expression level in the 54 ENKL patients (Figure 5J). These findings revealed that miR-497 specifically inhibits Bcl-w protein synthesis in ENKL cells.

Deletion of Bcl-w Suppresses XIST-Mediated ENKL Proliferation and Migration
We next examined the function of Bcl-w in XIST-mediated ENKL cell proliferation and migration. Silencing of Bcl-w by siRNA suppressed NK-92 cell proliferation and migration with or without XIST overexpression (Figures 6A-D and  Supplementary Figures 3A-C). We then investigated whether the Bcl-w inhibitor ABT-737 could be used to overcome the ENKL cell proliferation and migration induced by XIST overexpression. Similar to Bcl-w knockdown, ABT-737 treatment suppressed NK-92 cell proliferation and migration, even with XIST overexpression (Figures 6E,F). ABT-737 not only suppressed NK-92 cell proliferation but also caused cell loss ( Figure 6E). ABT-737 has been reported to induce apoptosis in multiple cancer cells, and we also found apoptotic signals in ABT-737-treated NK-92 cells using nucleus fragmentation stained with Hoechst-33258 ( Figure 6G). Therefore, our results indicated that miR-497 acts on Bcl-w to modulate ENKL proliferation induced by XIST.

DISCUSSION
Currently, abnormal lncRNA expression has been extensively detected and confirmed to be related to tumor occurrence. LncRNA XIST is reportedly able to accelerate metastasis through targeting miRNAs . Likewise, it has been shown to facilitate colon cancer development through the Wnt/β-catenin signaling pathway (Sun et al., 2018). Although research on XIST as an oncogene is rapidly increasing, no study has examined the role of XIST in ENKL patients. In the present study, we found increased XIST expression in the ENKL tissues of 54 patients; more importantly, high XIST expression was found to be associated with unfavorable prognosis, suggesting an oncogenic component of XIST involved in ENKL pathology.
LncRNAs have garnered increased attention because of their essential roles in normal physiological and pathogenic processes . XIST has been reported to be involved in the biological processes of cancer cells, and it is resistant to chemo-and radiotherapies. XIST can influence gastric cancer cell proliferation, migration, intrusion, and tumor growth by sponging miR-101 (Chen et al., 2016). XIST can also regulate the biological processes of bladder cancer cells by acting on miR-124 (Xiong et al., 2017). The present work indicated that XIST knockdown notably inhibited ENKL cell proliferation and migration, which agrees with the conclusions from other studies. It has been extensively acknowledged that lncRNA-miRNA-mRNA interactions assume an essential part in tumor occurrence, (Zhou et al., 2019) and previous studies have indicated that XIST plays an important role in cancers mainly by interacting with diverse miRNAs (Esquela-Kerscher and Slack, 2006). To thoroughly explore the mechanism of XIST in ENKL, we scanned the miRNA-lncRNA interaction database and selected the top five predicted miRNAs. We further analyzed the expression of these miRNAs in ENKL patients and found that miR-497 was downregulated. Furthermore, we verified that miR-497 is the downstream target of XIST, which mediates ENKL cell proliferation and migration. The dysregulation of miRNAs can trigger diverse cancers, including malignant lymphocytic tumors (Peng and Croce, 2016). Most known and characterized miRNAs are thought to act as tumor inhibitors or oncogenes, and their respective function is dependent on the cell type or has a tissue-specific context (Fabbri et al., 2008). MiR-497 has been reported to act as a tumor suppressor in multiple cancers, including lymphoma (Troppan et al., 2015). Furthermore, miR-497 has been reported to be the target of XIST in gastric cancer and hepatocellular carcinoma . Consistent with previous studies, we also found that miR-497 suppressed the XIST-induced ENKL tumor growth and metastasis, which is an important target in patients with high XIST expression.
Regarding miR-497 downstream transcripts, we found that Bcl-w is the downstream transcript target, which could be regulated through XIST/miR-497 axis. Impaired apoptosis signaling is a precondition for tumor occurrence . And the anti-apoptosis BCL-2 family proteins are major cell survival modulators that are frequently overexpressed in malignant tumors, resulting in augmented cancer cell survival (Gibson et al., 1996;Adams et al., 2017). Different from BCL-XL and BCL-2, the closest anti-apoptosis relative BCL-W is warranted for sperm development but not for other types (Hata et al., 2015). In recent years, several studies have revealed that Bcl-w is essential for B-cell survival and lymphomagenesis (Gibson et al., 1996). Bcl-w deprivation substantially inhibited MYC-modulated B-cell lymphoma occurrence owing to enhanced MYC-triggered B-cell apoptosis. Beyond cell death, pro-survival proteins from the BCL-2 family have been shown to contribute to the migratory ability of cancer cells, (Um, 2016;Gross and Katz, 2017) and the role of Bcl-w to this process has been delineated. It is reasonable that the anti-apoptotic function of Bcl-w contributes to survival of drug-resistant cells. As to the non-apoptotic role of Bcl-w, it was reported to enhance the migratory and invasive potentials of gastric cancer cells by facilitating the production of several types of extracellular matrix (ECM)-degrading proteinases (Bhatnagar et al., 2010). Secreted matrix metallopeptidase-2 (MMP-2) and urokinasetype plasminogen activator surface receptor (uPAR) have been demonstrated to activate focal adhesion kinase (FAK), which acts as an executioner of Bcl-w-dependent invasive phenotype of gastric cancer cells (Bae et al., 2009). In this study, we found that ENKL patients exhibit high expression of Bcl-w, which is . Each experiment was repeated for 3 times. *p < 0.05; **p < 0.01; ***p < 0.001. modulated by XIST/miR-497 signals. Furthermore, our data suggested that dysregulation of Bcl-W in ENKL promotes the cancer cell proliferation and migration. These findings reveal a novel mechanism for the dysregulation of Bcl-w in lymphomas, and targeting Bcl-w might be a potential strategy to overcome the ENKL progression and metastasis.
In summary, XIST acts as a miR-497 ceRNA by sponging miR-497, fighting with Bcl-w for connection with miR-497, and ultimately regulates ENKL cell proliferation and metastasis. Taken together, these findings indicate that XIST markedly promotes ENKL progression and that targeting the XIST/miR-497 axis can be a potential strategy to overcome the high cell proliferation and migration induced by abnormal Bcl-w expression.

DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

ETHICS STATEMENT
The studies involving human participants were reviewed and approved by the study was approved by the First Affiliated Hospital of Anhui Medical University and was conducted following relevant regulations and the Declaration of Helsinki. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.